China FDA approves ViiV's HIV drug Triumeq

China FDA approved Triumeq dolutegravir/abacavir/lamivudine (Triumec, 572-Trii, S-349572/S-265744/S-247303) from ViiV Healthcare Ltd. (Brentford, U.K.) to treat HIV/AIDS.

Triumeq is a once-daily tablet that comprises Tivicay dolutegravir, an HIV integrase inhibitor, plus the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. It is approved in >70 countries, including the U.S. and EU, to treat HIV-1 infection...